Poland· PL-100501940
Qalsody 100 mg roztwór do wstrzykiwań
A tofersen product containing tofersenum, registered in Poland by Biogen Netherlands B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tofersen is registered in 11 of 19 countries.
Countries holding a registration under ATC N07XX22 (tofersen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Tofersen · ATC N07XX22
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Tofersenum
- Manufacturer
- Biogen Netherlands B.V.
- Country
- Poland (PL)
- ATC code
- N07XX22
- ATC class
- Tofersen
- Defined daily dose
- 3.57 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05713219588287
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tofersen in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumQalsody 100 mgBiogen Netherlands
- CzechiaQALSODYBiogen Netherlands B.V., Badhoevedorp
- SpainQALSODY 100 MG SOLUCIÓN INYECTABLEBiogen Netherlands B.V.
- FinlandQalsodyBiogen Netherlands B.V.
- IrelandQalsody 100 mg solution for injectionBiogen Netherlands B.V.
- IcelandQalsodyBiogen Netherlands B.V.
- NetherlandsQalsody 100 mg oplossing voor injectieBiogen Netherlands B.V.
- SwedenQalsody 100 mg Injektionsvätska, lösningBiogen Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Qalsody
- Liechtenstein · Qalsody
- Norway · Qalsody
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/605c0240-0ce4-4304-be61-cb0f04522062 GET /v1/drugs/605c0240-0ce4-4304-be61-cb0f04522062?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "100 mg",
"packaging": "05713219588287 ¦ Rpz ¦ EU/1/23/1783/001 ¦ 157344\n1 fiol. 15 ml (6,7 mg/ml)",
"substance": "Tofersenum 100 mg",
"common_name": "Tofersenum",
"pl_product_id": "100501940",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": "2029-05-29"
}See everything about tofersen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.